Literature DB >> 2889491

Postjunctional alpha 2-adrenoceptors mediate venoconstriction in the hindquarters circulation of anaesthetized cats.

G A Bentley1, R E Widdop.   

Abstract

1 A study was made of the subtypes of postjunctional alpha-adrenoceptors which mediate arterial and venous constriction in the hindquarters circulation of anaesthetized cats, as measured by changes in perfusion pressure and vena cava blood flow, respectively. 2 It was found that, while noradrenaline caused constriction in both the arterial and venous compartments, methoxamine caused only arterial constriction. Clonidine and B-HT 920 also caused arterial and venous constriction although autodesensitization to both drugs occurred. 3 The ability of either prazosin or yohimbine to antagonize the constrictor effects of noradrenaline was also examined. It was found that the combination of both antagonist drugs abolished both the arterial and venous constrictor effects of noradrenaline. However, there was a greater prazosin-resistant response to noradrenaline in the venous compartment as compared with the arterial effects of noradrenaline. Yohimbine caused approximately equal reductions in the effect of noradrenaline in both arteries and veins, which was greater than that observed with prazosin. 4 These results suggest that, in the cat hindquarters, both alpha 1- and alpha 2-adrenoceptors are present in the arterial circulation, whereas there are mainly alpha 2-adrenoceptors in the venous circulation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2889491      PMCID: PMC1853635          DOI: 10.1111/j.1476-5381.1987.tb11303.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Regional variation in the alpha-adrenergic receptors in the canine resistance vessels.

Authors:  P T Horn; J D Kohli; J J Listinsky; L I Goldberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-02       Impact factor: 3.000

2.  Desensitization of the vascular contractile response to cumulative doses of alpha 2-adrenoceptor agonists.

Authors:  D W Cheung
Journal:  Can J Physiol Pharmacol       Date:  1986-10       Impact factor: 2.273

3.  Uneven distribution of postjunctional alpha 1-and alpha 2-like adrenoceptors in canine arterial and venous smooth muscle.

Authors:  J De Mey; P M Vanhoutte
Journal:  Circ Res       Date:  1981-06       Impact factor: 17.367

4.  Effects of prazosin and phenoxybenzamine on alpha- and beta-receptor-mediated responses in intestinal resistance and capacitance vessels.

Authors:  P Patel; D Bose; C Greenway
Journal:  J Cardiovasc Pharmacol       Date:  1981 Sep-Oct       Impact factor: 3.105

5.  alpha 1- and alpha 2-Adrenoceptor-mediated pressor and chronotropic effects in the rat and rabbit.

Authors:  J C McGrath; N A Flavahan; C E McKean
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

6.  Heterogeneity of postjunctional vascular alpha-adrenoceptors and handling of calcium.

Authors:  P M Vanhoutte
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

7.  Effects of sodium nitroprusside, isosorbide dinitrate, isoproterenol, phentolamine and prazosin on hepatic venous responses to sympathetic nerve stimulation in the cat.

Authors:  C V Greenway
Journal:  J Pharmacol Exp Ther       Date:  1979-04       Impact factor: 4.030

8.  An examination of pre- and postsynaptic alpha-adrenoceptors in the autoperfused rabbit hindlimb.

Authors:  H Madjar; J R Docherty; K Starke
Journal:  J Cardiovasc Pharmacol       Date:  1980 Sep-Oct       Impact factor: 3.105

Review 9.  Evidence for more than one type of post-junctional alpha-adrenoceptor.

Authors:  J C McGrath
Journal:  Biochem Pharmacol       Date:  1982-02-15       Impact factor: 5.858

10.  Presence of postsynaptic alpha 2-adrenoreceptors of predominantly extrasynaptic location in the vascular smooth muscle of the dog hind limb.

Authors:  S Z Langer; R Massingham; N B Shepperson
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.